Our Blog

 

Therapeutic potential of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) for management of patients with atherogenic dyslipidemia

By Heather Nelson Cortes PhD and Kevin C Maki PhD | Jul 10, 2019 | 0 Comments

Therapeutic potential of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) for management of patients with atherogenic dyslipidemia By Heather Nelson Cortes, PhD and Kevin C Maki, PhD   Atherosclerotic cardiovascular disease (ASCVD) is associated with a significant public health burden around the world.  It is further exacerbated by chronic lifestyle-related diseases, such as visceral obesity,

Read More

Serum Markers of Oxidative Stress to Assess Mortality Risk in Patients with Type 2 Diabetes

By Aly Becraft MS and Kevin C Maki PhD | Jul 10, 2019 | 0 Comments

Serum Markers of Oxidative Stress to Assess Mortality Risk in Patients with Type 2 Diabetes By Aly Becraft, MS and Kevin C Maki, PhD Hyperglycemia is thought to result in increased reactive oxygen species (ROS) production and weakened antioxidant capacity,1 which can make patients with type 2 diabetes (T2D) susceptible to elevated oxidative stress. Current

Read More

Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease

By Heather Nelson Cortes PhD and Kevin C Maki PhD | Jun 8, 2019 | 0 Comments

Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease By Heather Nelson Cortes, PhD and Kevin C Maki, PhD   Cardiovascular disease (CVD) continues to be the leading cause of death around the world and it is directly associated with blood levels of low-density lipoprotein cholesterol (LDL-C).1,2  In many clinical trials

Read More

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

By Aly Becraft MS and Kevin C Maki PhD | May 29, 2019 | 0 Comments

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy By Aly Becraft, MS and Kevin C Maki, PhD The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial was designed to assess the effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor, canagliflozin, on renal outcomes in patients with type 2

Read More

Oral Semaglutide versus Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes

By Aly Becraft MS and Kevin C Maki PhD | May 27, 2019 | 0 Comments

Oral Semaglutide versus Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes By Aly Becraft, MS and Kevin C Maki, PhD   The PIONEER3 trial was designed to compare the efficacy, long-term adverse event profile, and tolerability of an orally administered formulation of the glucagon-like peptide 1 receptor agonist (GLP-1RA), semaglutide, with the widely-used

Read More

Associations of Dietary Cholesterol and Egg Consumption with Incident Cardiovascular Disease and Total Mortality

By Kevin C Maki PhD and Heather Nelson Cortes PhD | May 2, 2019 | 0 Comments

Associations of Dietary Cholesterol and Egg Consumption with Incident Cardiovascular Disease and Total Mortality Associations of Dietary Cholesterol and Egg Consumption with Incident Cardiovascular Disease and Total Mortality   By Kevin C. Maki, PhD and Heather Nelson Cortes, PhD   Despite decades of research, the association between dietary cholesterol consumption, cardiovascular disease (CVD) and mortality

Read More

Association of Long-term Consumption of Sugar-Sweetened and Artificially Sweetened Beverages with Total and Cause-specific Mortality

By Heather Nelson Cortes PhD and Kevin C Maki PhD | Apr 26, 2019 | 0 Comments

Association of Long-term Consumption of Sugar-Sweetened and Artificially Sweetened Beverages with Total and Cause-specific Mortality By Heather Nelson Cortes, PhD and Kevin C Maki, PhD In the United States, sugar sweetened beverages (SSBs) account for the largest source of added sugar in the diet 1,2.  These types of drinks (e.g., carbonated, noncarbonated, fruit, sports) have

Read More

Effects of pioglitazone on risks for cardiovascular events and diabetes in patients with prediabetes and a history of stroke or transient ischemic attack

By Aly Becraft MS and Kevin C Maki PhD | Apr 16, 2019 | 0 Comments

Effects of pioglitazone on risks for cardiovascular events and diabetes in patients with prediabetes and a history of stroke or transient ischemic attack By Aly Becraft, MS and Kevin C Maki, PhD   Insulin resistance is an established risk factor for stroke and other adverse cardiovascular events.1,2 As many as 50% of patients with stroke

Read More

Bempedoic acid in conjunction with statin therapy for dyslipidemia management

By Aly Becraft MS and Kevin C Maki PhD | Apr 15, 2019 | 0 Comments

Bempedoic acid in conjunction with statin therapy for dyslipidemia management By Aly Becraft, MS; Kevin C. Maki, PhD Use of statins to reduce risk of cardiovascular disease is an effective treatment strategy,1 but the statin doses required to adequately reduce low density lipoprotein cholesterol (LDL-C) and non-high-density-lipoprotein cholesterol (non-HDL-C) levels and achieve optimal cardiovascular disease

Read More

The Effects of Icosapent Ethyl on Total Ischemic Events: An Analysis from REDUCE-IT

By Aly Becraft MS and Kevin C Maki PhD | Mar 26, 2019 | 0 Comments

The Effects of Icosapent Ethyl on Total Ischemic Events: An Analysis from REDUCE-IT By Aly Becraft, MS and Kevin C Maki, PhD   Statin therapy is highly effective for lowering low-density lipoprotein cholesterol (LDL-C), but many patients remain at risk for ischemic events, despite statin therapy.1 Elevated levels of triglycerides (TG) and TG-rich lipoproteins are

Read More